Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2017

01-04-2017 | Letter to the Editor

Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients

Authors: Yuki Osada, Hideki Arakaki, Satoshi Takanashi, Chisako Ito, Yoshinobu Aisa, Tomonori Nakazato

Published in: Medical Oncology | Issue 4/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival. A systematic review and meta-analysis. JAMA Oncol. 2016;. doi:10.​1001/​jamaoncol.​2015.​5932.
2.
Dahlen T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia. A population-based cohort study. Ann Intern Med. 2016;165(3):161–6.CrossRefPubMed
3.
Aichberger KJ, Herndihofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.CrossRefPubMed
4.
Breccia M, Colafigli G, Molica M, et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100–1.CrossRefPubMed
5.
Breccia M, Molica M, Zacheo I, et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular disease during nilotinib treatment. Ann Hematol. 2015;94:393–7.CrossRefPubMed
6.
Rea D, Mirault T, Raffoux E, et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia. 2015;29:1206–9.CrossRefPubMed
7.
Nishimura K, Okamura T, Watanabe M, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb. 2014;21:784–98.CrossRefPubMed
Metadata
Title
Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients
Authors
Yuki Osada
Hideki Arakaki
Satoshi Takanashi
Chisako Ito
Yoshinobu Aisa
Tomonori Nakazato
Publication date
01-04-2017
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0922-5

Other articles of this Issue 4/2017

Medical Oncology 4/2017 Go to the issue

Original Paper

Low microchimeric cell density in tumors suggests alternative antineoplastic mechanism

Original Paper

Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy

Review Article

The use of rapid and cost-effective blood-based biomarkers in combination with tumour TNM stage for individual head and neck cancer patient treatment selection

Review Article

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma

Short Communication

Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a “bedside-to-bench” approach

Original Paper

Percutaneous needle biopsy of mediastinal masses under C-arm conebeam CT guidance: diagnostic performance and safety
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits